Patents by Inventor Marcella A. Gilmore

Marcella A. Gilmore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DEGRADABLE CLOSTRIDIAL TOXINS
    Publication number: 20130330806
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Application
    Filed: August 16, 2013
    Publication date: December 12, 2013
    Applicant: Allergan, Inc.
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • DEGRADABLE CLOSTRIDIAL TOXINS
    Publication number: 20130288334
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Application
    Filed: March 18, 2013
    Publication date: October 31, 2013
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • DEGRADABLE CLOSTRIDIAL TOXINS
    Publication number: 20130273633
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Application
    Filed: March 18, 2013
    Publication date: October 17, 2013
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
    Patent number: 8518417
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a translocation facilitating domain and an enhanced targeting domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Grant
    Filed: July 11, 2007
    Date of Patent: August 27, 2013
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Joseph Francis, Ester G. Fernandez-Salas, Marcella A. Gilmore, Shengwen Li, Kei Roger Aoki
  • Degradable clostridial toxins
    Patent number: 8512992
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: August 20, 2013
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • MODIFIED CLOSTRIDIAL TOXINS WITH ENHANCED TRANSLOCATION CAPABILITY AND ENHANCED TARGETING ACTIVITY
    Publication number: 20130203148
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a translocation facilitating domain and an enhanced targeting domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Application
    Filed: July 11, 2007
    Publication date: August 8, 2013
    Inventors: Lance E. Steward, Joseph Francis, Ester G. Fernandez-Salas, Marcella A. Gilmore, Shengwen Li, Kei Roger Aoki
  • Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
    Patent number: 8460682
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: June 11, 2013
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
  • Multivalent clostridial toxins
    Patent number: 8273865
    Abstract: The present invention is directed to multivalent Clostridial toxin comprising more than one binding domain directed to a cell surface molecule of a target cell. Such modified toxins are useful as therapeutic compositions to prevent exocytosis and secretion by the target cell. Conditions in which such compositions may be useful include, without limitation, disorders of the sensory or motor nervous system, acute or chronic pain, cancer, pancreatitis, hyperhydrosis, glandular disorders, viral infections, cystic fibrosis and the like. The invention is also directed to methods of using and administering such a composition, and methods of treating a given condition using such a composition.
    Type: Grant
    Filed: September 16, 2010
    Date of Patent: September 25, 2012
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
  • Activatable clostridial toxins
    Patent number: 8273358
    Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: September 25, 2012
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Joseph Francis, Ester Fernandez-Salas, Sanjiv Ghanshani, Marcella A. Gilmore, Shengwen Li, J. Oliver Dolly, Kei Roger Aoki
  • Modified Clostridial Toxins with Enhanced Targeting Capabilities For Endogenous Clostridial Toxin Receptor Systems
    Publication number: 20120178140
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Application
    Filed: February 27, 2012
    Publication date: July 12, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
  • Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
    Patent number: 8128940
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Grant
    Filed: March 14, 2006
    Date of Patent: March 6, 2012
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei R. Aoki
  • Modified Clostridial Toxins with Altered Targeting Capabilities For Clostridial Toxin Target Cells
    Publication number: 20120052548
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Application
    Filed: October 26, 2011
    Publication date: March 1, 2012
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
  • Activatable clostridial toxins
    Patent number: 8071110
    Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: December 6, 2011
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Joseph Francis, Ester Fernandez-Salas, Sanjiv Ghanshani, Marcella A. Gilmore, Shengwen Li, J. Oliver Dolly, Kei Roger Aoki
  • DEGRADABLE CLOSTRIDIAL TOXINS
    Publication number: 20110294742
    Abstract: The specification discloses modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; polynucleotide molecules encoding modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; and method of producing modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain.
    Type: Application
    Filed: August 15, 2011
    Publication date: December 1, 2011
    Applicant: ALLERGAN, INC.
    Inventors: LANCE E. STEWARD, ESTER G. FERNANDEZ-SALAS, MARCELLA A. GILMORE, JOSEPH FRANCIS, SHENGWEN LI, KEI ROGER AOKI
  • Degradable Clostridial Toxins
    Publication number: 20110287517
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Application
    Filed: May 20, 2011
    Publication date: November 24, 2011
    Applicant: ALLERGAN, INC.
    Inventors: LANCE E. STEWARD, SANJIV GHANSHANI, ESTER FERNANDEZ-SALAS, MARCELLA A. GILMORE, JOSEPH FRANCIS, KEI ROGER AOKI
  • Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
    Patent number: 8052979
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Grant
    Filed: March 14, 2006
    Date of Patent: November 8, 2011
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
  • Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
    Patent number: 8022172
    Abstract: Clostridial toxin substrates comprising a lanthanide donor complex, an acceptor, and a Clostridial toxin recognition sequence including a cleavage site; methods for determining the activity of a Clostridial toxin from a test sample using such Clostridial toxin substrates; cell compositions comprising such Clostridial toxin substrates and a Clostridial toxin receptor; and methods for determining the activity of a Clostridial toxin from a test sample using such cell compositions.
    Type: Grant
    Filed: May 23, 2007
    Date of Patent: September 20, 2011
    Assignee: Allergan, Inc.
    Inventors: Dudley J. Williams, Marcella A. Gilmore, Lance E. Steward, Marc Verhagen, Kei Roger Aoki, Ester Fernandez-Salas
  • Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
    Patent number: 8021859
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: September 20, 2011
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
  • Assays of molecular or subcellular interactivity using depolarization after resonance transfer energy (DARET)
    Patent number: 7998749
    Abstract: The present invention provides a method of determining the proximity, or changes in the proximity of two or more molecular features labeled with fluorophores able to undergo DARET. In preferred embodiments the change in proximity of molecular features in a sample is correlated with changes in the fluorescence polarization of the sample, and may be monitored in real time.
    Type: Grant
    Filed: October 11, 2006
    Date of Patent: August 16, 2011
    Assignee: Allergan, Inc.
    Inventors: Marcella A. Gilmore, Dudley J. Williams, Lance E. Steward, Kei Roger Aoki
  • Degradable clostridial toxins
    Patent number: 7998489
    Abstract: The specification discloses modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; polynucleotide molecules encoding modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; and method of producing modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: August 16, 2011
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester G. Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Shengwen Li, Kei Roger Aoki